Pulse Biosciences (PLSE) Operating Leases (2019 - 2025)

Pulse Biosciences' Operating Leases history runs 7 years deep, the most recent figure standing at $7.5 million for Q4 2025.

• On a quarterly basis, Operating Leases changed 0.17% year-over-year to $7.5 million in Q4 2025; TTM through Dec 2025 was $7.5 million, a 0.17% change from a year earlier, with the FY2025 full-year figure at $7.5 million, changed 0.17% from the prior year.
• Operating Leases advanced to $7.5 million in Q4 2025 per PLSE's latest filing, from $6.4 million in the prior quarter.
• Across five years, Operating Leases topped out at $10.6 million in Q1 2021 and bottomed at $6.4 million in Q3 2025.
• The 5-year median for Operating Leases is $8.6 million (2024), against an average of $8.7 million.
• Biggest YoY gain for Operating Leases was 58.92% in 2021; the steepest drop was 25.23% in 2021.
• Year by year, Operating Leases stood at $8.1 million in 2021, then increased by 13.08% to $9.1 million in 2022, then dropped by 11.57% to $8.1 million in 2023, then declined by 6.72% to $7.5 million in 2024, then fell by 0.17% to $7.5 million in 2025.
• Per Business Quant, the three latest PLSE Operating Leases figures stand at $7.5 million (Q4 2025), $6.4 million (Q3 2025), and $6.8 million (Q2 2025).